Trial Search Results

Heparin and the Reduction of Thrombosis (HART) Trial

Heparin is frequently used in central venous catheters (CVCs) in post-operative cardiac patients. It remains unclear if a heparin infusion, compared to a normal saline infusion, prevents thrombosis of CVCs after surgery. This study will answer the question: does a low-dose heparin infusion (10 units/kg/h) prevent thrombosis, compared to a normal saline infusion, in patients less than one year of age after cardiac surgery?

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):

Intervention(s):

  • Drug: Heparin sulfate infusion at 10 units/kg/hour
  • Drug: Placebo infusion

Phase:

N/A

Eligibility


Inclusion Criteria:

   - All infants < 1 year of age undergoing cardiac surgery at Lucile Packard Children's
   Hospital & #xA

Exclusion Criteria:

   - Known coagulopathy

   - History of clinically significant bleeding (GI, cranial, pulmonary)

   - Need for therapeutic heparinization

   - ECMO

Ages Eligible for Study

N/A - 1 Year

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
David Axelrod
4156072463
Not Recruiting